Drug treatment of chronic myeloid leukaemia: A cost-effectiveness analysis of first- and second-line treatment;Medicamenteuze behandeling van chronische myeloïde leukemie: Een kosteneffectiviteitsanalyse van 1e- en 2e-lijnsbehandeling

Nederlands Tijdschrift voor Geneeskunde

Volumn 147, Issue 30, 2003, Pages 1460-1465

  Groot, M T ^a   Ossenkoppele, G J ^b   Kramer, M H H ^c   Van Den Boom, G ^c   Huijgens, P C ^b   Uyl De Groot, C A ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; HYDROXYUREA; IMATINIB;

ARTICLE; BLAST CELL CRISIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; LONG TERM CARE; QUALITY ADJUSTED LIFE YEAR;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; HUMANS; INTERFERON ALFA-2A; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0042825975     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kantarjian H, Melo JV, Tura S, Giralt S, Talpaz M. Chronic myelogenous leukemia: disease biology and current and future therapeutic strategies. Hematology (Am Soc Hematol Educ Program) 2000;90-109.
2. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
3. Hehlmann R, Hochhaus A, Berger U, Reiter A. Current trends in the management of chronic myelogenous leukemia. Ann Hematol 2000;79:345-54.
4. Reiter E, Greinix HT, Keil F, Brugger S, Rabitsch W, Schulenburg A, et al. Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia. Ann Hematol 1999;78:507-13.
5. 571 magnifies the therapeutic dilemma. Eur J Cancer 2001;37:561-8.
6. Baccarani M, Rosti G, de Vivo A, Bonifazi F, Russo D, Martinelli G, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002;99:1527-35.
7. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997;337: 223-9.
8. Kantarjian H, Sawyers CL, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
9. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
10. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38.
11. Liberato NL, Quaglini S, Barosi G. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. J Clin Oncol 1997; 15:2673-82.
12. Novartis Pharma. Glivec (imatinib). Registratiedossier. Deel 1B. Arnhem: Novartis Pharma; 2001.
13. Kuy A van der, redacteur. Farmacotherapeutisch kompas 2000. Amstelveen: College voor zorgverzekeringen; 2000.
14. Shepherd PC, Kluin-Nelemans HC, Richards S, Le Cessie S. A randomised comparison of low or high dose IFN-alpha in newly diagnosed CML patients shows now difference in major cytogenetic response rate or survival between the two groups. Results of MRC V & HOVON 20 trials. Blood 2001;98:abstractnr. 3034.
15. Uyl-de Groot CA, Gelderblom-den Hartog J, Huijgens PC, Willemze R, Ineveld BM van. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands. J Hematother Stem Cell Res 2001;101:187-92.
16. Smeenk FW, Ament AJ, Haastregt JC van, Witte LP de, Crebolder HF. Cost analysis of transmural home care for terminal cancer patients. Patient Educ Couns 1998;35:201-11.
17. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek, methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg. Amstelveen: College voor zorgverzekeringen; 2000.
18. 571 versus interferon + cytarabine as initial therapy for patients with CML: results of a randomised study. Proc Am Soc Clin Oncol 2002;21:1a.
19. Agthoven M van, Groot MT, Verdonck LF, Lowenberg B, Schattenberg AV, Oudshoorn M, et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant 2002;30:243-51.
20. Toenders WGM. Breedte geneesmiddelenpakket. Amstelveen: College voor zorgverzekeringen; 2001. p. 94.